With the progression of the condition, Diabetic Neuropathy prevalence also shifts. In fact, after 10 years of follow-up, the prevalence of diabetic neuropathy in T2DM patients rose from 8% to 42%. A cohort of patients with very mild T2DM who maintained good metabolic control had a prevalence of diabetic neuropathy in the Danish Addition research of newly diagnosed screen-detected T2D patients of 13% at study entry and a cumulative incidence of 10% over the 13-year follow-up period.
In contrast, 50% of participants in the BARI 2D trial, a large cohort of patients with more advanced T2DM and confirmed coronary artery disease, had confirmed Diabetic Neuropathy at baseline, and the 4-year cumulative incidence of diabetic neuropathy was 66-72% in those without neuropathy at baseline. Effective diagnostic, screening, and preventative efforts are crucial given how frequently diabetics develop neuropathy.
